SciVision Biotech
Creating a Better Vision through Science

According to the United Nations, by 2050, people aged over 60 will account for more than 20 percent of the world’s population. Of that 20 percent, a conservative estimate of 15 percent will have symptomatic osteoarthritis (OA), and one-third of these people will be severely disabled. As the prevalence of symptomatic knee OA grows among this aging population, driven by obesity and sedentary lifestyle, intra-articular injections of hyaluronic acid (viscosupplementation) have emerged as a sign of relief. Spearheading this arena is Kaohsiung-based SciVision Biotech.

Founded in 2001, SciVision Biotech is a high-quality biotech company listed on the Taiwan Stock Exchange Market. The company manufactures Hyaluronic acid products by leveraging a self-developed Cross-linked Hyaluronic Acid Platform (CHAP) to make the characteristics of Hyaluronic acid products precisely controllable. It can be widely used in the production of cross-linked Hyaluronic acid products with different types and physical properties. With excellent products, outstanding technology, customer-oriented services, and global development strategies, SciVision has become a leading company in the field of medical-grade Hyaluronic acid products."We leverage the platform as our core technology to produce every single product as it's a significant differentiator for us and a way to stay ahead of our competitors in the market," says Hatter Kuo, Vice General Manager at SciVision Biotech.

SciVision has made three breakthroughs and leading advances in the field of orthopedic treatment with its products that include joint cavity injections for the field of orthopedics, anti-adhesion products for the field of abdominal and orthopedic surgeries, and bone healing with the function of hyperplasia products (currently in the development stage). The company's single-shot joint cavity injection product has a long-lasting effect of up to 12 months. This product has been awarded in Taiwan and is available through Taiwan National Health Insurance in 15 famous medical centers and nearly 500 hospitals and clinics. The joint cavity injections help patients with degenerative joints relieve the pain and restore joint health and mobility. The anti-adhesion products help patients undergoing abdominal and orthopedic surgeries to have better wound healing and enable them to return to normal life as soon as possible. In fact, SciVision is one of the only two companies in the world that's capable of producing pure hyaluronic acid-based anti-adhesion products for postoperative surgeries, right from C-Section to minimally invasive orthopedic surgery. Besides, SciVision offers subcutaneous dermal fillers that enable patients to restore their youth and stay confident.

These products successfully overcome the shortcomings of similar products produced by traditional methods and offer higher biocompatibility, easy and fast operation, high viscosity, and long-lasting effect. “The one and only purpose of our products is to help patients be healthy and beautiful from inside out. As a global pharmaceutical company, we believe that in the field of orthopedic treatment solutions, we always need to have forward-looking and outstanding progress in order to satisfy the needs of doctors and users,” states Kuo. Despite the challenges of increasing operating costs and rigorous regulations in the field of medical devices, SciVision has been continuously providing safe and stable medical products that deliver long-lasting effects.

As a global pharmaceutical company, we believe that in the field of orthopedic treatment solutions, we always need to have forward-looking and outstanding progress in order to satisfy the needs of doctors and users

Kuo highlights that the company’s purpose is in its name as it represents “Science creates better visions, SciVision provides better solutions.”

As an R&D-based company, SciVision is continuously producing new products as per the market’s needs. The company invested heavily in the factory construction and advanced equipment in order to meet the ever stringent changes in pharmaceutical regulations and internally for the best operations and development of a high-standard pharmaceutical company. Moreover, SciVision has a newly constructed factory with a total area of 25,000 square meters. “We are in full compliance with the high standard regulations for medical device quality control system standards (ISO13485), good manufacturing practice (GMP), the United States Food and Drug Administration (USFDA) and International Pharmaceutical Inspection Agreement (PIC/S, GMP), and other specifications necessary to meet the medical regulations,” explains Kuo.

Since its founding 20 years ago, SciVision has been well-supported by an excellent R&D and production team, a rigorous and complete quality system, and professional management members, making it a renowned name in the industry known for its quality products. Today, the company’s products are sold in more than 20 countries around the world, with sales accumulated to 10 million doses. SciVisions’ esteemed clientele includes Galderma, Macopharma, Kalbe Farma, and many other famous distributors in every corner of the world.

SciVision has successfully positioned itself as a leader in the field of hyaluronic acid and a global pharmaceutical company. The company has also started exploring the possibilities of bone healing with the function of hyperplasia products, as this product is proven to be better than other products currently on the market. SciVision is confident and looking forward to this new product passing through human clinical trials, and it is expected to launch within the next three years. Currently, the company’s products are successfully marketed in more than 20 countries and regions, including Taiwan, China, Europe, Korea, Japan, the Middle East, Russia, South America, and Southeast Asia. Steering ahead, SciVision plans to expand its customer base in the world’s biggest pharmaceutical markets—U.S. and China. As for now, the company has only one injection dosage dermal filler product selling in China. Although SciVision has been registering several new products in these two markets, its joint cavity injections and anti-adhesion products are not yet available for sale in these two markets. “Despite this, SciVision has shown great potential for future operation and development. In the future, our products, technologies, and customization services will gradually improve over time and prove that SciVision is the best and the only choice for global customers,” notes Kuo.